Vytorin vs. Livalo

See how Vytorin and Livalo compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Vytorin combines two cholesterol-lowering drugs in one tablet, while Livalo relies on statin action alone.

  • Both are taken once daily, but Vytorin typically costs $600 to $650 a month versus $315 to $410 for Livalo without insurance.

  • Vytorin has trial evidence for reducing heart attacks and strokes after a cardiac event, while Livalo has fewer drug interactions due to minimal liver enzyme metabolism.

Vytorin vs. Livalo Drug Summary

Vytorin

Vytorin combines ezetimibe, a cholesterol absorption inhibitor, with simvastatin, a statin, in a single tablet. It's taken once daily to lower LDL cholesterol, total cholesterol, triglycerides, and Apo B, and to raise HDL, in adults with high cholesterol or certain inherited cholesterol disorders.

Livalo

Livalo (pitavastatin) is a statin that blocks cholesterol production in the liver. It's taken once daily to lower LDL cholesterol, total cholesterol, and triglycerides in adults with high cholesterol or mixed dyslipidemia, and is also approved for children 8 and older with an inherited cholesterol disorder.

Vytorin vs. Livalo Side Effects

Vytorin

Most common
Myalgia (up to 3.6%)
Diarrhea (up to 2.8%)
Headache (up to 5.8%)
Increased ALT (up to 3.7%)

Livalo

Most common
Myalgia (1.9% to 3.1%)
Diarrhea (1.5% to 2.6%)
Constipation (1.5% to 3.6%)
Back pain (1.4% to 3.9%)

Vytorin vs. Livalo Dosage

Vytorin

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg/10 mg once daily At the start
Maximum dose 10 mg/80 mg once daily If needed
Dose changes 3 increases As tolerated

Livalo

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1 mg once daily At the start
Maximum dose 4 mg once daily If needed
Dose changes 2 increases As tolerated

Vytorin vs. Livalo Indications

Vytorin

Vytorin is FDA-approved to lower LDL cholesterol, total cholesterol, triglycerides, and Apo B, and to raise HDL, in adults with primary hyperlipidemia. It's also approved for two rare inherited conditions, homozygous familial hypercholesterolemia and homozygous sitosterolemia, that respond poorly to statins alone.

  • Primary hyperlipidemia (LDL, total cholesterol, triglycerides, Apo B)

  • Raising HDL cholesterol

  • Homozygous familial hypercholesterolemia

  • Homozygous sitosterolemia

Livalo

Livalo is FDA-approved to lower LDL cholesterol, total cholesterol, and triglycerides in adults with primary hyperlipidemia or mixed dyslipidemia. It's also approved for heterozygous familial hypercholesterolemia in adults and children 8 and older, and is sometimes used off-label for primary prevention of cardiovascular disease.

  • Primary hyperlipidemia or mixed dyslipidemia

  • Heterozygous familial hypercholesterolemia (adults)

  • Heterozygous familial hypercholesterolemia (children 8+)

  • Off-label: primary prevention of ASCVD

Vytorin vs. Livalo Pros and Cons

Vytorin

Vytorin pairs a statin with a cholesterol absorption inhibitor, giving it two mechanisms to lower LDL in a single tablet. It carries a higher risk of muscle-related side effects at its top dose and more potential drug interactions than single-agent statins. Its list price is also notably higher than lower-dose statin-only options.

Pros

  • Two cholesterol-lowering mechanisms in one tablet

  • Trial evidence for reduced cardiovascular events after a heart attack (IMPROVE-IT)

  • Approved for rare conditions like homozygous FH and sitosterolemia

Cons

  • Higher myopathy and rhabdomyolysis risk at the 80 mg dose

  • More drug interactions through the CYP3A4 pathway

  • Roughly $600 to $650 per month without insurance, well above Livalo's price

Livalo

Livalo is a single-mechanism statin with minimal liver enzyme interactions, making it a lower-interaction option for patients on multiple medications. It doesn't include a second cholesterol-blocking ingredient, so its LDL reduction may be less pronounced than combination therapy. Its lower price and pediatric approval are notable advantages.

Pros

  • Minimal CYP3A4 metabolism means fewer drug interactions

  • Approved for children as young as 8 with familial hypercholesterolemia

  • Roughly $315 to $410 per month without insurance, lower than Vytorin

Cons

  • Relies on one mechanism, so LDL lowering may be more modest

  • Not FDA-approved for homozygous FH or sitosterolemia

  • Contraindicated with cyclosporine due to increased drug exposure

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.